Religox is indicated for the management of adult patients with advanced prostate cancer.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Relugolix is a non-peptide, small-molecule GnRH receptor antagonist. It binds competitively to pituitary GnRH receptors, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in suppression of testosterone production, which is essential in controlling prostate cancer progression.
ওয়েবসাইট থেকে অর্ডার করার সহজ ভিডিও গাইড।
অ্যাপ থেকে অর্ডারের সহজ ভিডিও গাইড
অ্যাপ ডাউনলোডDownload ePharma App বিস্তারিত গাইড ›Detailed App Ordering GuideCommon (≥10%):
Less common / Rare:
Loading Dose: 360 mg orally on Day 1.
Maintenance Dose: 120 mg once daily, taken at the same time each day (with or without food).
Missed Dose:
Pediatric use: Not established.
Geriatric use: No clinically significant difference observed compared to younger patients.
P-gp inhibitors: Avoid co-administration. If necessary, take Religox first, maintain a 6-hour gap, and monitor closely.
Strong CYP3A inducers (combined with P-gp): Avoid. If unavoidable, increase dose to 240 mg once daily.
Not indicated for use in women.
Safety and efficacy in pregnancy and lactation have not been established.
QT prolongation: Monitor in patients at risk or on QT-prolonging drugs.
Embryo-fetal toxicity: May cause fetal harm; advise contraception for men with female partners of reproductive potential.
Fertility: Relugolix may impair male fertility.
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.